@article{ATM30512,
author = {Joan Tymon-Rosario and Burak Zeybek and Chanhee Han and Alessandro D. Santin},
title = {Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Ovarian cancer is the most common cause of gynecologic cancer death in the United States with 22,530 newly diagnosed cases and 13,980 deaths annually. There has been a miniscule, approximately 2.3% decrease, each year in the death rates from ovarian cancer over the past few decades (1). Although most patients with advanced ovarian cancer respond to initial platinum-based chemotherapy, 70% will relapse and ultimately become resistant, refractory, or unable to receive platinum-based chemotherapy owing to cumulative toxic effects (2,3). This has led to a paradigm shift in the approach to the treatment of ovarian cancer with precision medicine and additional targeted therapies becoming part of the standard treatment regimen.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/30512}
}